Pulmonary alveolar proteinosis

Chronic Respiratory Disease

Volumn 3, Issue 3, 2006, Pages 149-159

  Ioachimescu, Octavian C ^a   Kavuru, M S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Autoantibodies; Bronchoalveolar lavage; Granulocyte macrophage colony stimulating factor (GM CSF); Pulmonary alveolar proteinosis; Pulmonary surfactant

Indexed keywords

AUTOANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; LUNG SURFACTANT;

CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DYSPNEA; GENE MUTATION; HUMAN; IMAGING SYSTEM; LABORATORY TEST; LUNG ALVEOLUS PROTEINOSIS; LUNG LAVAGE; LUNG TRANSPLANTATION; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SPIROMETRY; THORAX RADIOGRAPHY;

ANIMALS; ANTIGENS, NEOPLASM; BIOPSY; BRONCHOALVEOLAR LAVAGE FLUID; DIAGNOSIS, DIFFERENTIAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; IRRIGATION; L-LACTATE DEHYDROGENASE; LUNG; LUNG TRANSPLANTATION; MACROPHAGES, ALVEOLAR; MUCINS; PULMONARY ALVEOLAR PROTEINOSIS;

EID: 33747105239     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1191/1479972306cd101rs     Document Type: Review

References (148)

1. Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258: 1123-42.
2. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002; 166: 215-35.
3. Ramirez J, Nyka W, McLaughlin J. Pulmonary alveolar proteinosis. Diagnostic technics and observations. N Engl J Med 1963; 268: 165-71.
4. Mclaughlin JS, Ramirez J. Pulmonary alveolar proteinosis: treatment by pulmonary segmental flooding. Am Rev Respir Dis 1964; 89: 745-52.
5. Ramirez J, Campbell GD. Pulmonary alveolar proteinosis. endobronchial treatment. Ann Intern Med 1965; 63: 429-41.
6. Ramirez J, Savard EV, Hawkins JE. Biological effect of pulmonary washings from cases of alveolar proteinosis. Am Rev Respir Dis 1966; 94: 244-46.
7. Ramirez RJ, Halprin G. Pulmonary alveolar proteinosis - physiologic observations during and after pulmonary lavage. Bol Asoc Med PR 1973; 65: 183-87.
8. Dranoff G, Crawford AD, Sadelain M et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264: 713-16.
9. Stanley E, Lieschke GJ, Grail D et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994; 91: 5592-96.
10. Kitamura T, Tanaka N, Watanabe J et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999; 190: 875-80.
11. Thomassen MJ, Yi T, Raychaudhuri B, Malur A, Kavuru MS. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin Immunol 2000; 95: 85-92.
12. Goldstein LS, Kavuru MS, Curtis-McCarthy P, Christie HA, Farver C, Stoller JK. Pulmonary alveolar proteinosis: clinical features and outcomes. Chest 1998; 114: 1357-62.
13. deMello DE, Lin Z. Pulmonary alveolar proteinosis: a review. Pediatr Pathol Mol Med 2001; 20: 413-32.
14. Prakash UB, Barham SS, Carpenter HA, Dines DE, Marsh HM. Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc 1987; 62: 499-518.
15. Ben Dov I, Kishinevski Y, Roznman J et al. Pulmonary alveolar proteinosis in Israel: ethnic clustering. Isr Med Assoc J 1999; 1: 75-78.
16. Hoffman RM, Dauber JH, Rogers RM. Improvement in alveolar macrophage migration after therapeutic whole lung lavage in pulmonary alveolar proteinosis. Am Rev Respir Dis 1989; 139: 1030-32.
17. Prakash UB, Barham SS, Carpenter HA, Dines DE, Marsh HM. Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc 1987; 62: 499-518.
18. Ikegami M, Ueda T, Hull W et al. Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. Am J Physiol 1996; 270: L650-58.
19. Pattle RE. Properties, function and origin of the alveolar lining layer. Nature 1955; 175: 1125-26.
20. Meaney S, Bonfield TL, Hansson M, Babiker A, Kavuru MS, Thomassen MJ. Serum cholestenoic acid as a potential marker of pulmonary cholesterol homeostasis: increased levels in patients with pulmonary alveolar proteinosis. J Lipid Res 2004; 45: 2354-60.
21. Veldhuizen R, Nag K, Orgeig S, Possmayer F. The role of lipids in pulmonary surfactant. Biochim Biophys Acta 1998; 1408: 90-108.
22. Turley SD, Andersen JM, Dietschy JM. Rates of sterol synthesis and uptake in the major organs of the rat in vivo. J Lipid Res 1981; 22: 551-69.
23. Voyno-Yasenetskaya TA, Dobbs LG, Erickson SK, Hamilton RL. Low density lipoprotein- and high density lipoprotein-mediated signal transduction and exocytosis in alveolar type II cells. Proc Natl Acad Sci USA 1993; 90: 4256-60.
24. Bai Y, Galetskiy D, Damoc E et al. High resolution mass spectrometric alveolar proteomics: identification of surfactant protein SP-A and SP-D modifications in proteinosis and cystic fibrosis patients. Proteomics 2004; 4: 2300-2309.
25. Reed JA, Whitsett JA. Granulocyte-macrophage colony-stimulating factor and pulmonary surfactant homeostasis. Proc Assoc Am Physicians 1998; 110: 321-32.
26. Burgess AW, Camakaris J, Metcalf D. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J Biol Chem 1977; 252: 1998-2003.
27. Miyatake S, Otsuka T, Yokota T, Lee F, Arai K. Structure of the chromosomal gene for granulocyte-macrophage colony stimulating factor: comparison of the mouse and human genes. EMBO J 1985; 4: 2561-68.
28. Gough NM, Gough J, Metcalf D et al. Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature 1984; 309: 763-67.
29. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med 1992; 327: 28-35.
30. Gearing DP, King JA, Gough NM, Nicola NA. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J 1989; 8: 3667-76.
31. Hayashida K, Kitamura T, Gorman DM, Arai K, Yokota T, Miyajima A. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proc Natl Acad Sci USA 1990; 87: 9655-59.
32. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 4491-508.
33. Dranoff G, Mulligan RC. Activities of granulocyte-macrophage colony-stimulating factor revealed by gene transfer and gene knockout studies. Stem Cells 1994; 12(Suppl 1): 173-82.
34. Reed JA, Ikegami M, Robb L, Begley CG, Ross G, Whitsett JA. Distinct changes in pulmonary surfactant homeostasis in common beta-chain- and GM-CSF-deficient mice. Am J Physiol Lung Cell Mol Physiol 2000; 278: L1164-71.
35. Nishinakamura R, Nakayama N, Hirabayashi Y et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 1995; 2: 211-22.
36. Robb L, Drinkwater CC, Metcalf D et al. Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc Natl Acad Sci USA 1995; 92: 9565-69.
37. Reed JA, Ikegami M, Cianciolo ER et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol 1999; 276: L556-63.
38. Nishinakamura R, Wiler R, Dirksen U et al. The pulmonary alveolar proteinosis in granulocyte macrophage colony-stimulating factor/interleukins 3/5 beta c receptor-deficient mice is reversed by bone marrow transplantation. J Exp Med 1996; 183: 2657-62.
39. Cooke KR, Nishinakamura R, Martin TR et al. Persistence of pulmonary pathology and abnormal lung function in IL-3/GM-CSF/IL-5 beta c receptor-deficient mice despite correction of alveolar proteinosis after BMT. Bone Marrow Transplant 1997; 20: 657-62.
40. Ikegami M, Whitsett JA, Chroneos ZC et al. IL-4 increases surfactant and regulates metabolism in vivo. Am J Physiol Lung Cell Mol Physiol 2000; 278: L75-80.
41. Kavuru MS, Sullivan FJ, Piccin R, Thomassen MJ, Stoller JK. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161: 1143-48.
42. Seymour JF, Begley CG, Dirksen U et al. Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis. Blood 1998; 92: 2657-67.
43. Carraway MS, Ghio AJ, Carter JD, Piantadosi CA. Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161: 1294-99.
44. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003; 349: 2527-39.
45. Bonfield TL, Russell D, Burgess S, Malur A, Kavuru MS, Thomassen MJ. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002; 27: 481-86.
46. Parker LA, Novotny DB. Recurrent alveolar proteinosis following double lung transplantation. Chest 1997; 111: 1457-58.
47. Teja K, Cooper PH, Squires JE, Schnatterly PT. Pulmonary alveolar proteinosis in four siblings. N Engl J Med 1981; 305: 1390-92.
48. Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993; 328: 406-10.
49. Nogee LM, Garnier G, Dietz HC et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994; 93: 1860-63.
50. Beers MF, Hamvas A, Moxley MA et al. Pulmonary surfactant metabolism in infants lacking surfactant protein B. Am J Respir Cell Mol Biol 2000; 22: 380-91.
51. Dirksen U, Nishinakamura R, Groneck P et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997; 100: 2211-17.
52. Buechner HA, Ansari A. Acute silico-proteinosis. A new pathologic variant of acute silicosis in sandblasters, characterized by histologic features resembling alveolar proteinosis. Dis Chest 1969; 55: 274-78.
53. Xipell JM, Ham KN, Price CG, Thomas DP. Acute silicoproteinosis. Thorax 1977; 32: 104-11.
54. Miller RR, Churg AM, Hutcheon M, Lom S. Pulmonary alveolar proteinosis and aluminum dust exposure. Am Rev Respir Dis 1984; 130: 312-15.
55. McDonald JW, Alvarez F, Keller CA. Pulmonary alveolar proteinosis in association with household exposure to fibrous insulation material. Chest 2000; 117: 1813-17.
56. McCunney RJ, Godefroi R. Pulmonary alveolar proteinosis and cement dust: a case report. J Occup Med 1989; 31: 233-37.
57. Keller CA, Frost A, Cagle PT, Abraham JL. Pulmonary alveolar proteinosis in a painter with elevated pulmonary concentrations of titanium. Chest 1995; 108: 277-80.
58. Dawkins SA, Gerhard H, Nevin M. Pulmonary alveolar proteinosis: a possible sequel of NO2 exposure. J Occup Med 1991; 33: 638-41.
59. Carnovale R, Zornoza J, Goldman AM, Luna M. Pulmonary alveolar proteinosis: its association with hematologic malignancy and lymphoma. Radiology 1977; 122: 303-306.
60. Aymard JP, Gyger M, Lavallee R, Legresley LP, Desy M. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung? Cancer 1984; 53: 954-56.
61. Cordonnier C, Fleury-Feith J, Escudier E, Atassi K, Bernaudin JF. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med 1994; 149: 788-94.
62. Gacouin A, Le Tulzo Y, Suprin E et al. Acute respiratory failure caused by secondary alveolar proteinosis in a patient with acute myeloid leukemia: a case report. Intensive Care Med 1998; 24: 265-67.
63. Dirksen U, Hattenhorst U, Schneider P et al. Defective expression of granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 receptor common beta chain in children with acute myeloid leukemia associated with respiratory failure. Blood 1998; 92: 1097-103.
64. Haworth JC, Hoogstraten J, Taylor H. Thymic alymphoplasia. Arch Dis Child 1967; 42: 40-54.
65. Webster JR, Jr, Battifora H, Furey C, Harrison RA, Shapiro B. Pulmonary alveolar proteinosis in two siblings with decreased immunoglobulin A. Am J Med 1980; 69: 786-89.
66. Yousem SA. Alveolar lipoproteinosis in lung allograft recipients. Hum Pathol 1997; 28: 1383-86.
67. Wagner U, Staats P, Moll R, Feek U, Vogelmeier C, Groneberg DA. Imatinib-associated pulmonary alveolar proteinosis. Am J Med 2003; 115: 674.
68. Israel RH, Magnussen CR. Are AIDS patients at risk for pulmonary alveolar proteinosis? Chest 1989; 96: 641-42.
69. Ruben FL, Talamo TS. Secondary pulmonary alveolar proteinosis occurring in two patients with acquired immune deficiency syndrome. Am J Med 1986; 80: 1187-90.
70. Bakhos R, Gattuso P, Arcot C, Reddy VB. Pulmonary alveolar proteinosis: an unusual association with Mycobacterium avium-intracellulare infection and lymphocytic interstitial pneumonia. South Med J 1996; 89: 801-802.
71. Couderc LJ, Bernaudin JF, Epardeau B, Caubarrere I. Pulmonary alveolar proteinosis and disseminated Mycobacterium avium infection. Respir Med 1996; 90: 641-42.
72. Reyes JM, Putong PB. Association of pulmonary alveolar lipoproteinosis with mycobacterial infection. Am J Clin Pathol 1980; 74: 478-85.
73. Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore) 1994; 73: 103-109.
74. Pascual J, Gomez Aguinaga MA, Vidal R et al. Alveolar proteinosis and nocardiosis: a patient treated by bronchopulmonary lavage. Postgrad Med J 1989; 65: 674-77.
75. Tran VN, Vojtek AM, Bernaudin JF, Escudier E, Fleury-Feith J. Pulmonary alveolar proteinosis associated with Pneumocystis carinii. Ultrastructural identification in bronchoalveolar lavage in AIDS and immunocompromised non-AIDS patients. Chest 1990; 98: 801-805.
76. Gumpert BC, Nowacki MR, Amundson DE. Pulmonary alveolar lipoproteinosis. Remission after antibiotic treatment. West J Med 1994; 161: 66-68.
77. Asamoto H, Kitaichi M, Nishimura K, Itoh H, Izumi T. [Primary pulmonary alveolar proteinosis-clinical observation of 68 patients in Japan]. Nihon Kyobu Shikkan Gakkai Zasshi 1995; 33: 835-45.
78. Shah PL, Hansell D, Lawson PR, Reid KB, Morgan C. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000; 55: 67-77.
79. Anton HC, Gray B. Pulmonary alveolar proteinosis presenting with pneumothorax. Clin Radiol 1967; 18: 428-31.
80. Oliva PB, Vogel JH. Reactive pulmonary hypertension in alveolar proteinosis. Chest 1970; 58: 167-68.
81. Briens E, Delaval P, Mairesse MP et al. [Pulmonary alveolar proteinosis]. Rev Mal Respir 2002; 19: 166-82.
82. Lee KN, Levin DL, Webb WR, Chen D, Storto ML, Golden JA. Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations. Chest 1997; 111: 989-95.
83. Arcasoy SM, Lanken PN. Images in clinical medicine. Pulmonary alveolar proteinosis. N Engl J Med 2002; 347: 2133.
84. Godwin JD, Muller NL, Takasugi JE. Pulmonary alveolar proteinosis: CT findings. Radiology 1988; 169: 609-13.
85. Rubinstein I, Mullen JB, Hoffstein V. Morphologic diagnosis of idiopathic pulmonary alveolar lipoproteinosis-revisited. Arch Intern Med 1988; 148: 813-16.
86. Johkoh T, Itoh H, Muller NL et al. Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings. Radiology 1999; 211: 155-60.
87. Holbert JM, Costello P, Li W, Hoffman RM, Rogers RM. CT features of pulmonary alveolar proteinosis. AJR Am J Roentgenol 2001; 176: 1287-94.
88. Hudson AR, Halprin GM, Miller JA, Kilburn KH. Pulmonary interstitial fibrosis following alveolar proteinosis. Chest 1974; 65: 700-702.
89. Miller PA, Ravin CE, Smith GJ, Osborne DR. Pulmonary alveolar proteinosis with interstitial involvement. AJR Am J Roentgenol 1981; 137: 1069-71.
90. Clague HW, Wallace AC, Morgan WK. Pulmonary interstitial fibrosis associated with alveolar proteinosis. Thorax 1983; 38: 865-66.
91. Mazzone P, Thomassen MJ, Kavuru M. Our new understanding of pulmonary alveolar proteinosis: what an internist needs to know. Cleve Clin J Med 2001; 68: 977-72, 984.
92. Martin RJ, Rogers RM, Myers NM. Pulmonary alveolar proteinosis: shunt fraction and lactic acid dehydrogenase concentration as aids to diagnosis. Am Rev Respir Dis 1978; 117: 1059-62.
93. Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis. A review and an update. Chest 1997; 111: 460-66.
94. Maygarden SJ, Iacocca MV, Funkhouser WK, Novotny DB. Pulmonary alveolar proteinosis: a spectrum of cytologic, histochemical, and ultrastructural findings in bronchoalveolar lavage fluid. Diagn Cytopathol 2001; 24: 389-95.
95. Chou CW, Lin FC, Tung SM, Liou RD, Chang SC. Diagnosis of pulmonary alveolar proteinosis: usefulness of papanicolaou-stained smears of bronchoalveolar lavage fluid. Arch Intern Med 2001; 161: 562-66.
96. Costello JF, Moriarty DC, Branthwaite MA, Turner-Warwick M, Corrin B. Diagnosis and management of alveolar proteinosis: the role of electron microscopy. Thorax 1975; 30: 121-32.
97. Gilmore LB, Talley FA, Hook GE. Classification and morphometric quantitation of insoluble materials from the lungs of patients with alveolar proteinosis. Am J Pathol 1988; 133: 252-64.
98. Hoffman RM, Rogers RM. Serum and lavage lactate dehydrogenase isoenzymes in pulmonary alveolar proteinosis. Am Rev Respir Dis 1991; 143: 42-46.
99. Takahashi T, Munakata M, Suzuki I, Kawakami Y. Serum and bronchoalveolar fluid KL-6 levels in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 1998; 158: 1294-98.
100. Presneill JJ, Nakata K, Inoue Y, Seymour JF. Pulmonary alveolar proteinosis. Clin Chest Med 2004; 25: 593-613, viii.
101. Honda Y, Takahashi H, Shijubo N, Kuroki Y, Akino T. Surfactant protein-A concentration in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Chest 1993; 103: 496-99.
102. Kuroki Y, Sano H, Sohma H, Akino T. [Pulmonary surfactant proteins: structure, function, pathophysiology]. Tanpakushitsu Kakusan Koso 1998; 43: 834-46.
103. Doyle IR, Bersten AD, Nicholas TE. Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure. Am J Respir Crit Care Med 1997; 156: 1217-29.
104. Doyle IR, Nicholas TE, Bersten AD. Serum surfactant protein-A levels in patients with acute cardiogenic pulmonary edema and adult respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152: 307-17.
105. Bonfield TL, John N, Malur A et al. Elevated monocyte chemotactic proteins 1, 2, and 3 in pulmonary alveolar proteinosis are associated with chemokine receptor suppression. Clin Immunol 2005; 114: 79-85.
106. Iyonaga K, Suga M, Yamamoto T, Ichiyasu H, Miyakawa H, Ando M. Elevated bronchoalveolar concentrations of MCP-1 in patients with pulmonary alveolar proteinosis. Eur Respir J 1999; 14: 383-89.
107. Mikami T, Yamamoto Y, Yokoyama M, Okayasu I. Pulmonary alveolar proteinosis: diagnosis using routinely processed smears of bronchoalveolar lavage fluid. J Clin Pathol 1997; 50: 981-84.
108. Hamvas A, Nogee LM, Mallory GB, Jr et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr 1997; 130: 231-39.
109. Ladeb S, Fleury-Feith J, Escudier E, Tran VN, Bernaudin JF, Cordonnier C. Secondary alveolar proteinosis in cancer patients. Support Care Cancer 1996; 4: 420-26.
110. Venkateshiah SB, Thomassen MJ, Kavuru MS. Pulmonary alveolar proteinosis. Clinical manifestations and optimal treatment strategies. Treat Respir Med 2004; 3: 217-27.
111. Kavuru MS, Popovich M. Therapeutic whole lung lavage: a stop-gap therapy for alveolar proteinosis. Chest 2002; 122: 1123-24.
112. Ramirez J, Kieffer RF, Jr, Ball WC, Jr. Bronchopulmonary lavage in man. Ann Intern Med 1965; 63: 819-28.
113. Wasserman K, Blank N, Fletcher G. Lung lavage (alveolar washing) in alveolar proteinosis. Am J Med 1968; 44: 611-17.
114. Kao D, Wasserman K, Costley D, Benfield JR. Advances in the treatment of pulmonary alveolar proteinosis. Am Rev Respir Dis 1975; 111: 361-63.
115. Sunderland WA, Klein RL. Heparin absorption during heparin-saline lung lavage in a patient with pulmonary alveolar proteinosis. Chest 1973; 63: 1033-34.
116. Hammon WE, McCaffree DR, Cucchiara AJ. A comparison of manual to mechanical chest percussion for clearance of alveolar material in patients with pulmonary alveolar proteinosis (phospholipidosis). Chest 1993; 103: 1409-12.
117. Bingisser R, Kaplan V, Zollinger A, Russi EW. Whole-lung lavage in alveolar proteinosis by a modified lavage technique. Chest 1998; 113: 1718-19.
118. Cheng SL, Chang HT, Lau HP, Lee LN, Yang PC. Pulmonary alveolar proteinosis: treatment by bronchofiberscopic lobar lavage. Chest 2002; 122: 1480-85.
119. Avecillas J, Ghamande S, Kavuru M. Comparison between unilateral and bilateral sequential whole-lung lavage in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2002; 165: A653.
120. Rogers RM, Levin DC, Gray BA, Moseley LW, Jr. Physiologic effects of bronchopulmonary lavage in alveolar proteinosis. Am Rev Respir Dis 1978; 118: 255-64.
121. Gale ME, Karlinsky JB, Robins AG. Bronchopulmonary lavage in pulmonary alveolar proteinosis: chest radiograph observations. AJR Am J Roentgenol 1986; 146: 981-85.
122. Murayama J, Fukuda K, Sato T et al. Pulmonary alveolar proteinosis. Xe-133 scintigraphic findings before and after bronchopulmonary lavage. Clin Nucl Med 1993; 18: 123-25.
123. Selecky PA, Wasserman K, Benfield JR, Lippmann M. The clinical and physiological effect of whole-lung lavage in pulmonary alveolar proteinosis: a ten-year experience. Ann Thorac Surg 1977; 24: 451-61.
124. Ben Abraham R, Greenfeld A, Rozenman J, Ben Dov I. Pulmonary alveolar proteinosis: step-by-step perioperative care of whole lung lavage procedure. Heart Lung 2002; 31: 43-49.
125. Rogers RM, Szidon JP, Shelburne J, Neigh JL, Shuman JF, Tantum KR. Hemodynamic response of the pulmonary circulation to broncho-pulmonary lavage in man. N Engl J Med 1972; 286: 1230-33.
126. Aguinaga MA, Santos P, Renes E et al. Hemodynamic changes during whole bronchoalveolar lavage in two cases of pulmonary alveolar proteinosis. Intensive Care Med 1991; 17: 421-23.
127. Smith JD, Millen JE, Safar P, Robin ED. Intrathoracic pressure, pulmonary vascular pressures and gas exchange during pulmonary lavage. Anesthesiology 1970; 33: 401-405.
128. Seymour JF, Dunn AR, Vincent JM, Presneill JJ, Pain MC. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. N Engl J Med 1996; 335: 1924-25.
129. Seymour JF, Presneill JJ, Schoch OD et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001; 163: 524-31.
130. Mazzone PJ, Sullivan EJ, Piccin R, Stoller JK, Thomassen MJ, Kavuru MS. OM-CSF therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161(Suppl): A888.
131. Bonfield TL, Kavuru MS, Thomassen MJ. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002; 105: 342-50.
132. Venkateshiah SB, Yan T, Bonfield TL, Thomassen MJ, Czich C, Kavuru MS. Recombinant human GM-CSF therapy in pulmonary alveolar proteinosis (PAP): an open label phase II clinical trial. Chest 2004; 126 [4(Suppl)]: 755S.
133. Valdes L, Pose A, Alvarez D, Ventura M. [GM-CSF: a therapeutic alternative to the bronchoalveolar lavage in the treatment of alveolar proteinosis]. Med Clin (Barc) 2003; 120: 117.
134. de Vega MG, Sanchez-Palencia A, Ramirez A, Cervera S, Aneiros J. GM-CSF therapy in pulmonary alveolar proteinosis. Thorax 2002; 57: 837.
135. Barraclough RM, Gillies AJ. Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy. Thorax 2001; 56: 664-65.
136. Khanjari F, Watier H, Domenech J, Asquier E, Diot P, Nakata K. GM-CSF and proteinosis. Thorax 2003; 58: 645.
137. Acosta O, Maranes I, Perez A, Hernandez AI, Bello MD, Lopez Y. [Therapeutic efficacy of GM-CSF in pulmonary alveolar proteinosis]. Arch Bronconeumol 2002; 38: 191-93.
138. Sherter CB, Mark EJ. Case 2-2001: a 42-year-old woman with acute worsening of chronic dyspnea and cough. N Engl J Med 2001; 344: 212-20.
139. Schoch OD, Schanz U, Koller M et al. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax 2002; 57: 277-80.
140. Lieschke GJ, Cebon J, Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 2634-43.
141. Anderson PM, Markovic SN, Sloan JA et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999; 5: 2316-23.
142. Wylam ME, Katzmann JA. Aerosolized GM-CSF improves pulmonary function in idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161 (Suppl): A889.
143. Rao RD, Anderson PM, Arndt CA, Wettstein PJ, Markovic SN. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol 2003; 26: 493-98.
144. Orriols R, Ferrer J, Tura JM, Xaus C, Coloma R. Sicca syndrome and silicoproteinosis in a dental technician. Eur Respir J 1997; 10: 731-34.
145. Beccaria M, Luisetti M, Rodi G et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 2004; 23: 526-31.
146. Larson RK, Gordinier R. Pulmonary alveolar proteinosis. report of six cases, review of the literature, and formulation of a new theory. Ann Intern Med 1965; 62: 292-312.
147. Davidson JM, Macleod WM. Pulmonary alveolar proteinosis. Br J Dis Chest 1969; 63: 13-28.
148. Mazzone P, Kavuru MS. Pulmonary alveolar proteinosis: recent advances. Seminars in Respiratory and Critical Care Medicine 2002; 23: 115-26.